CAR-T Cell targeting CD19 (Qilu Cell Therapy)

靶向CD19的CRA-T细胞（齐鲁细胞）

Report date: 2025/04/02 13:36:23

Base Information

Drug NameCAR-T Cell targeting CD19 (Qilu Cell Therapy)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsUpdating
Therapy Area/IndicationsLymphomaLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShandong Qilu Cell Treapy Engineering&Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShandong Qilu Cell Treapy Engineering&Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphomaLeukemia, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A